HomeCirculationVol. 106, No. 12Pulmonary Embolism and Deep Vein Thrombosis Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBPulmonary Embolism and Deep Vein Thrombosis Samuel Z. Goldhaber, MD and Ruth B. Morrison, RN, BSN, CVN Samuel Z. GoldhaberSamuel Z. Goldhaber From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass. Search for more papers by this author and Ruth B. MorrisonRuth B. Morrison From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass. Search for more papers by this author Originally published17 Sep 2002https://doi.org/10.1161/01.CIR.0000031167.64088.F6Circulation. 2002;106:1436–1438The heart pumps oxygenated blood through the aorta to smaller arteries. After the blood supplies nutrients to vital organs, it returns through veins for reoxygenation in the lungs (Figures 1 and 2). Blood clots called deep vein thrombi (DVT) often develop in the deep leg veins. Pulmonary embolism (PE) occurs when clots break off from vein walls and travel through the heart to the pulmonary arteries. The broader term venous thromboembolism (VTE) refers to DVT, PE, or to a combination of both. Download figureDownload PowerPointFigure 1. The arterial (red) and venous systems (blue) are depicted. The left ventricle (LV) ejects oxygenated blood into the aorta, which circulates blood to vital organs. Deoxygenated blood travels through the venous system to the right atrium, right ventricle, and pulmonary artery. Adapted with permission from MediClip, Clinical Cardiopulmonary Images 1997, CCP01026.TIF, Williams & Wilkins, Baltimore, Md.Download figureDownload PowerPointFigure 2. Deoxygenated blood returns to the heart and lungs for reoxygenation. SVC indicates superior vena cava; IVC, inferior vena cava; RA, right atrium; RV, right ventricle; and PA, pulmonary artery. Adapted with permission from MediClip, Clinical Cardiopulmonary Images 1997, CATHRHT.TIF, Williams & Wilkins, Baltimore, Md.What Is the Epidemiology?VTE poses a public health threat with an estimated incidence in the United States of 250 000 to 2 million cases per year. Predisposition to VTE arises from acquired conditions, inherited disorders, or both. Many of the acquired risk factors can be modified, thus lessening the likelihood of PE or DVT.What Are the Acquired Risk Factors?Long-haul air travel is the most talked-about risk factor for PE. Other acquired risk factors include obesity, cigarette smoking, hypertension, immobilization, surgery, and trauma. Chronic medical illnesses such as congestive heart failure, chronic obstructive pulmonary disease, and cancer also predispose to PE. PE is also a prominent women’s health issue. Risk factors include oral contraceptives, pregnancy, and hormone replacement therapy.What Are the Inherited Disorders?Heredity plays an important role in a patient’s susceptibility to PE. We are just beginning to develop genetic tests (such as factor V Leiden and the prothrombin gene mutation) that can identify those who are predisposed. The presence of these risk factors is sometimes called a prothrombotic or thrombophilic state.How Is the Diagnosis Established?DVT most often originates in the calf, with a persistent cramping or “charley horse” that intensifies over several days. Leg swelling and discoloration may accompany the increase in discomfort. Upper-extremity DVT may cause otherwise unexplained upper arm or neck swelling. The most frequently used diagnostic imaging test is the noninvasive venous ultrasound examination.Many patients with PE have a vague sense that something is wrong but have difficulty defining or describing the problem. Consequently, they often delay seeking medical attention. At times, because symptoms are so vague and nonspecific, medical professionals will diagnose anxiety rather than PE. To establish the diagnosis of PE, the most frequently used noninvasive imaging test is the rapid-speed chest computed tomography (CT) scan.What Are the Warning Signals of PE?Unexplained shortness of breath (the most common symptom of PE)Chest discomfort, usually worse with a deep breath or coughingA general sense of anxiety or nervousnessLightheadedness or blacking outWhat Should I Expect at the Hospital?Definitely Expect:Questions about symptoms of chest or leg discomfort, breathing difficulties, or lightheadednessQuestions about whether you or your family members have suffered prior VTEA check of your blood pressure, pulse rate, breathing rate, heart, lungs, and legsAn ECG and chest x-rayPossibly Expect:A blood test (D-dimer) that screens for PE (If results are normal, PE is extremely unlikely.)A chest CT scan, which directly images blood clots causing blockages in the pulmonary arteriesA lung scan, which indirectly identifies areas of decreased blood flow in the lung tissue as a consequence of PEBlood tests to detect a prothrombotic state, especially in relatively young and otherwise healthy patients with PE or DVTWhat Treatment Will I Receive?PE can range from mild to severe. Mild PE is managed with blood thinners (anticoagulation). Severe PE requires additional measures, such as clot busters (thrombolytic therapy) or embolectomy, a procedure in which the clot is removed with either a catheter or surgery.Anticoagulation begins with a combination of 2 blood thinners: (1) heparin, administered intravenously or by injection, and (2) warfarin, an oral blood thinner. Heparin comes in 2 principal forms. The traditional unfractionated form ordinarily requires intravenous administration. There is no fixed dose for this type of heparin. Instead, the dose is titrated to a blood test called the partial thromboplastin time. This blood test is usually performed several times daily for the first few days and then once daily thereafter. More recently, low-molecular-weight heparins have begun replac-ing unfractionated heparin. Low-molecular-weight heparins are ordinarily prescribed in proportion to the patient’s weight, require no blood testing, and necessitate injection once or twice daily.We overlap heparin treatment with warfarin until the oral blood thinner becomes effective, usually after 5 to 10 days of combined therapy. We determine the proper dose of warfarin by a blood test reported as the International Normalized Ratio (INR). The target INR range is usually between 2.0 and 3.0. Interactions with food, alcohol, and other drugs can dramatically alter the INR. Sometimes, major fluctuations in the INR occur for no apparent reason. Too high an INR may result in bleeding as a side effect. Too low an INR may result in recurrent clotting. Patients may need their INR checked every few weeks or months, according to the stability of the readings. It is important for patients to keep a record of their values over time.PE is usually treated in the hospital with intravenous unfractionated heparin as a bridge to warfarin. In contrast, DVT can often be managed successfully on an outpatient basis with low-molecular-weight heparin injections as a bridge to oral anticoagulation with warfarin. The most controversial area in VTE therapy is the optimal duration of warfarin anticoagulation. The current recommendation is usually at least 6 months of anticoagulation, but it can sometimes be longer, according to individual patient circumstances.In patients who cannot tolerate anticoagulation or those for whom anticoagulation fails, a permanent metal filter is inserted into the inferior vena cava, the largest vein below the heart, to prevent large blood clots from reaching the pulmonary arteries and causing PE. Unfortunately, the filter devices do not halt the clotting process. Their presence predisposes to future venous clots on or below the filter.PreventionMaintaining ideal body weight with a healthy nutritional program and exercise regimen will generally reduce the likelihood of venous thrombosis. Specific other measures are shown below:To prevent immobility or inactivity: Walk, jog, bicycle, or swim.To prevent obesity: Limit caloric intake, exercise, and avoid saturated fats.To prevent VTE during air travel: Drink extra water, walk if feasible, wear vascular compression stockings, and avoid alcohol.To quit cigarette smoking: Use nicotine patch, gum, or spray, or consider the prescription drug bupropion.To control hypertension: Self-check blood pressure, and report elevated readings to primary care provider.To deal with a known genetic predisposition to VTE: Alert your healthcare provider about the family history and any abnormal blood tests related to a clotting tendency.To prevent VTE after trauma or surgery: Discuss with the treating physician the implementation of measures such as mechanical compression boots for the legs and/or blood thinners given either intravenously or as injections.To prevent VTE during a hospitalization precipitated by a medical condition: Discuss with the treating physician measures such as mechanical compression boots for the legs and/or blood thinners given either intravenously or as injections.To prevent VTE when planning birth control: Discuss VTE risks, and consider alternatives to oral contraceptives.To prevent VTE during pregnancy: Consider daily self-injected heparin if considered at high risk of VTE.To prevent VTE during hormone replacement therapy: Keep in mind that VTE risks with hormone replacement therapy are similar to those of oral contraceptives.FootnotesCorrespondence to Samuel Z. Goldhaber, MD, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail [email protected]Supplemental Reading1 Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998; 339: 93–104.CrossrefMedlineGoogle Scholar2 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353: 1386–1389.CrossrefMedlineGoogle Scholar3 Goldhaber SZ, ed. Frequently asked questions of the Pulmonary Embolism Support Group, Brigham and Women’s Hospital. Available at: http://icoper.cineca.com/faq_icoper.htm. Accessed August 23, 2002.Google Scholar4 Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001; 119: 132S–175S.CrossrefMedlineGoogle Scholar5 Goldhaber SZ, Ridker PM. Thrombosis and Thromboembolism. New York, NY: Marcel Dekker, Inc; 2002.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Varshney A, Bansal A, Agarwal A, Mishra V and Badal T (2022) A Comparative Study of Deep Learning Models for Detecting Pulmonary Embolism Advanced Computing, 10.1007/978-3-030-95502-1_7, (82-98), . Yan L, Jin X, Yan X, Peng J, Li Z and He B (2022) Combined use of extracorporeal membrane oxygenation with interventional surgery for acute pancreatitis with pulmonary embolism: A case report, World Journal of Clinical Cases, 10.12998/wjcc.v10.i12.3899, 10:12, (3899-3906), Online publication date: 26-Apr-2022. Kyriakoulis K, Kokkinidis D, Kyprianou I, Papanastasiou C, Archontakis-Barakakis P, Doundoulakis I, Bakoyiannis C, Giannakoulas G and Palaiodimos L (2020) Venous thromboembolism in the era of COVID-19, Phlebology: The Journal of Venous Disease, 10.1177/0268355520955083, 36:2, (91-99), Online publication date: 1-Mar-2021. Garcia M, Sterling K, Kahn S, Comerota A, Jaff M, Ouriel K, Weinberg I, Herman K, Leung D, Dexter D, Williams D, Gagne P, Razdan R, Winokur R, Dwivedi A, Sista A, Butler B, Johnson D, Kim P, Davis C, Feldtman R, Kee S, Leon L and Mannava K (2020) Ultrasound‐Accelerated Thrombolysis and Venoplasty for the Treatment of the Postthrombotic Syndrome: Results of the ACCESS PTS Study, Journal of the American Heart Association, 9:3, Online publication date: 4-Feb-2020. Demir H, Gulsun T, Ozkan M, Nemutlu E, Sahin S and Öner L (2020) Assessment of Dose Proportionality of Rivaroxaban Nanocrystals, AAPS PharmSciTech, 10.1208/s12249-020-01776-z, 21:6, Online publication date: 1-Aug-2020. Di Minno A, Ambrosino P, Calcaterra I and Di Minno M (2020) COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies, Seminars in Thrombosis and Hemostasis, 10.1055/s-0040-1715456, 46:07, (763-771), Online publication date: 1-Oct-2020. Ettefagh L, Jerome M, Porter J, Monfared H and Burke D (2019) Screening for occult lower-extremity deep vein thrombosis on admission to acute inpatient rehabilitation: A cross sectional, prospective study, The Journal of the International Society of Physical and Rehabilitation Medicine, 10.4103/jisprm.jisprm_42_19, 2:3, (110), . Kumar S and Suryawanshi H (2019) Role of microRNAs in cardiovascular diseases and their therapeutic implications AGO-Driven Non-Coding RNAs, 10.1016/B978-0-12-815669-8.00009-9, (233-259), . Wu H, Kim H, Tang Y, Yao J and Jiang X (2019) Fiber-optic laser-ultrasound transducer using carbon nanoparticles for intravascular sonothrombolysis 2019 IEEE 19th International Conference on Nanotechnology (IEEE-NANO), 10.1109/NANO46743.2019.8993894, 978-1-7281-2892-4, (261-264) de Jong L, Gout-Zwart J, van den Bosch M, Koops M and Postma M (2019) Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis, Journal of Medical Economics, 10.1080/13696998.2018.1563404, 22:4, (306-318), Online publication date: 3-Apr-2019. Wo Y, Brisbois E, Bartlett R and Meyerhoff M (2018) Improving the hemocompatibility of catheters via NO release/generation Hemocompatibility of Biomaterials for Clinical Applications, 10.1016/B978-0-08-100497-5.00013-6, (431-455), . Gombert A, Barbati M, Grommes J, Kurstjens R, deWolf M, Wittens C and Jalaie H (2017) Wound complications after common femoral vein endophlebectomy: Influence on outcome, Phlebology: The Journal of Venous Disease, 10.1177/0268355517714712, 33:6, (407-417), Online publication date: 1-Jul-2018. Ong H, Gokavarapu S, Al-Qamachi L, Yin M, Su L, Ji T and Zhang C (2017) Justification of routine venous thromboembolism prophylaxis in head and neck cancer reconstructive surgery, Head & Neck, 10.1002/hed.24914, 39:12, (2450-2458), Online publication date: 1-Dec-2017. Papadakis G, Karantanas A and Perisinakis K (2017) “Pulmonary embolism diagnostics of pregnant patients: What is the recommended clinical pathway considering the clinical value and associated radiation risks of available imaging tests?”, Physica Medica, 10.1016/j.ejmp.2017.07.017, 43, (178-185), Online publication date: 1-Nov-2017. Bahadori S, Immins T and Wainwright T (2017) The effect of calf neuromuscular electrical stimulation and intermittent pneumatic compression on thigh microcirculation, Microvascular Research, 10.1016/j.mvr.2017.01.001, 111, (37-41), Online publication date: 1-May-2017. Zhu J, Wang Z, Kim Y, Bae S, Tao C, Gong J and Bae K (2017) Analysis of contrast time–enhancement curves to optimise CT pulmonary angiography, Clinical Radiology, 10.1016/j.crad.2016.11.018, 72:4, (340.e9-340.e16), Online publication date: 1-Apr-2017. Kim J, Lindsey B, Chang W, Dai X, Stavas J, Dayton P and Jiang X (2017) Intravascular forward-looking ultrasound transducers for microbubble-mediated sonothrombolysis, Scientific Reports, 10.1038/s41598-017-03492-4, 7:1, Online publication date: 1-Dec-2017. Amin A and Marrs J (2016) Direct Oral Anticoagulants for the Management of Thromboembolic Disorders, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029615601492, 22:7, (605-616), Online publication date: 1-Oct-2016. Keller K, Geyer M, Beule J, Coldewey M, Balzer J and Dippold W (2015) Concomitant history of cancer in acute pulmonary embolism is connected with poorer outcome, Acta Haematologica Polonica, 10.1016/j.achaem.2015.08.002, 46:5, (378-384), Online publication date: 1-Nov-2015. Keller K, Geyer M, Beule J, Coldewey M, Balzer J and Dippold W (2015) Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular dysfunction in acute pulmonary embolism, Thoracic Cancer, 10.1111/1759-7714.12226, 6:5, (584-588), Online publication date: 1-Sep-2015. Neufeld E, Négrier C, Arkhammar P, el Fegoun S, Simonsen M, Rosholm A and Seremetis S (2015) Safety update on the use of recombinant activated factor VII in approved indications, Blood Reviews, 10.1016/S0268-960X(15)30006-0, 29, (S34-S41), Online publication date: 1-Jun-2015. Hull C, Hopkins C, Purdy N, Lloyd R and Harris J (2014) A case of unprovoked venous thromboembolism in a marathon athlete presenting atypical sequelae: What are the chances?, Scandinavian Journal of Medicine & Science in Sports, 10.1111/sms.12262, 25:5, (699-705), Online publication date: 1-Oct-2015. Piazza G, Hohlfelder B and Goldhaber S (2015) Long-Term Management of Venous Thromboembolism: Strategies for Reducing the Risk of Recurrence Handbook for Venous Thromboembolism, 10.1007/978-3-319-20843-5_10, (93-100), . Montero-Baker M, Braun J, Weinkauf C and Leon L (2015) Technological Advances in Endovascular Surgery Technological Advances in Surgery, Trauma and Critical Care, 10.1007/978-1-4939-2671-8_28, (323-354), . Hull C and Harris J (2015) Venous Thromboembolism in Physically Active People: Considerations for Risk Assessment, Mainstream Awareness and Future Research, Sports Medicine, 10.1007/s40279-015-0360-5, 45:10, (1365-1372), Online publication date: 1-Oct-2015. Meetoo D, Ochieng B and Fatani T (2014) Deep vein thrombosis: an underestimated threat, Journal of Operating Department Practitioners, 10.12968/jodp.2014.2.7.323, 2:7, (323-329), Online publication date: 2-Nov-2014. Bozkurt B and Mann D (2014) Update: Shortness of Breath, Circulation, 10.1161/CIRCULATIONAHA.113.006129, 129:15, Online publication date: 15-Apr-2014. Pan C, Liu H, Wang Y and Ding H (2014) Phase transformation and mechanical behaviors of vena cava filter modified by deposition of copper–titanium coating, Materials Research Bulletin, 10.1016/j.materresbull.2014.08.042, 60, (217-221), Online publication date: 1-Dec-2014. Akwaa F and Spyropoulos A (2014) The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism, Current Medical Research and Opinion, 10.1185/03007995.2014.951425, 30:11, (2179-2190), Online publication date: 1-Nov-2014. Chung W, Lin C, Chang S, Lu C and Kao C (2014) Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study, Journal of Thrombosis and Haemostasis, 10.1111/jth.12518, 12:4, (452-458), Online publication date: 1-Apr-2014. Lee M, Kim M, Han J, Park J, Lee K and Ryu H (2014) Pregnancy-associated pulmonary embolism during the peripartum period: An 8-year experience at a single center, Obstetrics & Gynecology Science, 10.5468/ogs.2014.57.4.260, 57:4, (260), . Hull C and Harris J (2013) Venous Thromboembolism and Marathon Athletes, Circulation, 128:25, (e469-e471), Online publication date: 1-Dec-2013. Wadajkar A, Santimano S, Rahimi M, Yuan B, Banerjee S and Nguyen K (2013) Deep vein thrombosis: Current status and nanotechnology advances, Biotechnology Advances, 10.1016/j.biotechadv.2012.08.004, 31:5, (504-513), Online publication date: 1-Sep-2013. Kim J and Kim Y (2013) Pulmonary embolism and deep vein thrombosis related to oral contraceptive use, Obstetrics & Gynecology Science, 10.5468/ogs.2013.56.4.273, 56:4, (273), . Palmer J, Bozas G, Stephens A, Johnson M, Avery G, O’Toole L and Maraveyas A (2013) Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients, BMC Health Services Research, 10.1186/1472-6963-13-235, 13:1, Online publication date: 1-Dec-2013. Harrington D (2013) Preventing and Recognizing Venous Thromboembolism After Obstetric and Gynecologic Surgery, Nursing for Women's Health, 10.1111/1751-486X.12051, 17:4, (325-329), Online publication date: 1-Aug-2013. Sang Cheol Park , Chapman B and Bin Zheng A Multistage Approach to Improve Performance of Computer-Aided Detection of Pulmonary Embolisms Depicted on CT Images: Preliminary Investigation, IEEE Transactions on Biomedical Engineering, 10.1109/TBME.2010.2063702, 58:6, (1519-1527) Lee Y and Player M (2011) Developments in factor Xa inhibitors for the treatment of thromboembolic disorders, Medicinal Research Reviews, 10.1002/med.20183, 31:2, (202-283), Online publication date: 1-Mar-2011. Crannage A and Murphy J (2011) Evaluation of the Implementation of an Anticoagulation Management Protocol at a Community Hospital, Journal of Pharmacy Practice, 10.1177/0897190011406124, 24:4, (404-408), Online publication date: 1-Aug-2011. McCutcheon T (2009) Superior Mesenteric Vein Thrombosis After Bowel Resection in Patients With Inflammatory Bowel Disease, Gastroenterology Nursing, 10.1097/SGA.0b013e31819de3fc, 32:2, (85-91), Online publication date: 1-Mar-2009. Breen P, Galvin O, Grace P and Laighin G (2007) Doppler ultrasound measurements of venous return in the popliteal vein 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 10.1109/IEMBS.2007.4352457, 978-1-4244-0787-3, (978-981) Goldhaber S (2007) Venous Disease Cardiovascular Medicine, 10.1007/978-1-84628-715-2_82, (1705-1716), . Varga E, Sturm A, Misita C and Moll S (2005) Homocysteine and MTHFR Mutations, Circulation, 111:19, (e289-e293), Online publication date: 17-May-2005. CRAWFORD S (2005) Factoring the risks of factor V Leiden, Nursing, 10.1097/00152193-200503000-00017, 35:3, (26), Online publication date: 1-Mar-2005. Goldhaber S and Fanikos J (2004) Prevention of Deep Vein Thrombosis and Pulmonary Embolism, Circulation, 110:16, (e445-e447), Online publication date: 19-Oct-2004. Gilmour Jr R (2005) New approaches for identifying antiarrhythmic drug targets, Expert Opinion on Therapeutic Targets, 10.1517/14728222.8.1.1, 8:1, (1-5), Online publication date: 1-Feb-2004. Koschel M (2004) Pulmonary Embolism, AJN, American Journal of Nursing, 10.1097/00000446-200406000-00029, 104:6, (46-50), Online publication date: 1-Jun-2004. Ornstein D and Cushman M (2003) Factor V Leiden, Circulation, 107:15, (e94-e97), Online publication date: 22-Apr-2003.Goldhaber S and Grasso-Correnti N (2002) Treatment of Blood Clots, Circulation, 106:20, (e138-e140), Online publication date: 12-Nov-2002. Sucharitha D, Sai D, Lahari M and Bee M (2021) Computer Assisted System for Detecting Pulmonary Embolism in Lungs, International Journal of Recent Technology and Engineering (IJRTE), 10.35940/ijrte.D6584.1110421, 10:4, (89-94) Gromadziński L, Paukszto Ł, Skowrońska A, Holak P, Smoliński M, Łopieńska-Biernat E, Lepiarczyk E, Lipka A, Jastrzębski J and Majewska M (2021) Transcriptomic Profiling of Femoral Veins in Deep Vein Thrombosis in a Porcine Model, Cells, 10.3390/cells10071576, 10:7, (1576) September 17, 2002Vol 106, Issue 12 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000031167.64088.F6PMID: 12234943 Originally publishedSeptember 17, 2002 PDF download Advertisement